Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation. (PubMed, Front Immunol) - Oct 4, 2026 - "Clinical programmes illustrate divergent outcomes: iza-bren provides regulatory validation of the modality, whereas experience with MEDI4276, zanidatamab zovodotin and REGN5093-M114 shows that enhanced binding or internalisation does not guarantee sustainable development. Importantly, much of the mechanistic and combination evidence for immune activation still derives from monospecific ADCs; immune benefit should therefore not be attributed to bispecificity itself without direct evidence. Future progress should integrate human pharmacokinetic/pharmacodynamic data, target-pair and immune-contexture biomarkers, dose-exposure-toxicity relationships and comparative value over optimized monospecific ADCs."
Journal • Review • Breast Cancer • Esophageal Squamous Cell Carcinoma • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • EGFR • ERBB3
|
|
Jun-Feng Ye; Rong Huang; Yang Li; Yu Li; Zhi-Qiang San
|